𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Remineralization of enamel by a saliva substitute designed for use by irradiated patients

✍ Scribed by Ira L. Shannon; John N. Trodahl; Edgar N. Starcke


Publisher
John Wiley and Sons
Year
1978
Tongue
English
Weight
392 KB
Volume
41
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis


A saliva substitute, VA-OraLube, was evaluated for ability to reharden dental enamel and to relieve intraoral soft tissue symptoms in patients receiving radiotherapy for malignancies of the head and neck. Treatments of 15, 30 and 60 minutes rehardened enamel by 3.1%, 4.0%, and 5.5%, respectively. In the second experiment, treatment for 60 minutes with the complete solution rehardened enamel by 5.2%. Omitting calcium, phosphorus and/or fluoride from the formulation greatly decreased this rehardening potential. Treatment of enamel with fresh whole saliva induced rehardening at a 7.3% level in comparison to the 5.5% and 5.2% derived by using the saliva substitute. Since the xerostomic patient usually uses the product very frequently, there is a remineralization potential of significant consequence. A total of 125 xerostomic patients used the saliva substitute on an ad lib basis over a period of 4 months. Patient responses indicated a very high level of acceptance and the virtual elimination of troublesome problems previously associated with the dry mouth state.


πŸ“œ SIMILAR VOLUMES


ChemInform Abstract: Design of Reaction
✍ Keisuke Asano; Seijiro Matsubara πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons βš– 26 KB πŸ‘ 1 views

## Abstract An interfacial medium is assembled in H~2~O by an amphiphilic imidazolium salt to form a hydrophobic membrane including an interface consisting of ammonium species.

A phase I/II trial of neoadjuvant chemot
✍ Jean Viallet; Marc-AndrΓ© Brassard; Luis Souhami; Joseph Ayoub; Pierre Del Vecchi πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 108 KB πŸ‘ 2 views

## BACKGROUND. Both locoregional and distant disease control remains poor in the treatment of Stage III nonsmall cell lung carcinoma (NSCLC). This trial was conducted to evaluate the tolerance and responses of patients with NSCLC given a neoadjuvant regimen of cisplatin and vinorelbine chemotherapy